NEW YORK , Nov. 26, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global gastroparesis drugs market size is estimated to grow by USD 1.42 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 3.69% during the forecast period. Rising global burden of diabetes is driving market growth, with a trend towards increasing growth opportunities in emerging markets. However, stringent regulatory guidelines poses a challenge.Key market players include Abbott Laboratories, AbbVie Inc., Aclipse Therapeutics, ANI Pharmaceuticals Inc., Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Eisai Co. Ltd., Evoke Pharma Inc., GlaxoSmithKline Plc, Ipca Laboratories Ltd., Johnson and Johnson, Medtronic Plc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Processa Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Theravance Biopharma Inc., Vanda Pharmaceuticals Inc., and Neurogastrx Inc.. Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Market Driver The Gastroparesis Drugs Market is witnessing significant growth due to the rising prevalence of Gastroparesis, a digestive disorder characterized by delayed emptying of the stomach. Neurogastrx's tradipitant is a promising innovation, joining metoclopramide, metopimazine, deudomperidone, and prokinetic agents in symptom management. Diabetes, lifestyles (alcohol consumption, tobacco), and surgical procedures contribute to gastroparesis. Diabetic cases, especially those with autonomic neuropathy, are a major focus. Companies like Evoke Pharma and ANI Pharmaceuticals are leading the market with FDA-cleared drugs. GI symptoms like nausea, vomiting, and abdominal discomfort lead to nutrient absorption complications. Erythromycin and antiemetics are common treatments, but new clinical trials explore alternatives like Reglan. PubMed Central hosts numerous studies on gastroparesis, including Acute cholecystitis and Acute pancreatitis. Innovative drugs, such as those addressing blood sugar regulation, enteral nutrition, and feeding intolerance, are in development. Hospitals and specialized care centers offer surgical interventions for severe cases. Vendors in the gastrointestinal drugs market are expanding their businesses in emerging economies to tap into the growing number of individuals with undiagnosed and untreated gastrointestinal disorders. For instance, the incidence and prevalence of chronic gastrointestinal disorders in Asia , particularly in China and India , have been rising. To capitalize on this trend, companies are increasing their R&D efforts and manufacturing capacities in these regions. Abbott, for example, is expanding its R&D teams in Brazil , India , and China to enhance its product offerings and launch new solutions. This strategic expansion will create significant revenue opportunities and strengthen the market's growth trajectory. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! The Gastroparesis market faces challenges due to the complexities of the condition, which includes neurogastric disorders like Neurogastrx's tradipitant, metopimazine, deudomperidone, and metoclopramide. Diabetes, lifestyles factors such as alcohol consumption and tobacco use, and surgical procedures are common triggers. Innovative drugs are in development for symptom management, including Evoke Pharma's FDA-cleared prokinetic agent, and ANI Pharmaceuticals' deudomperidone. Diabetic gastroparesis cases are prevalent in hospitals, requiring specialized care. GI symptoms like nausea, vomiting, abdominal discomfort, and nutrient absorption complications hinder quality of life. Autonomic neuropathy, acute cholecystitis, and acute pancreatitis are associated conditions. Erythromycin and antiemetics like Reglan are commonly used, but clinical trials continue for new treatments. PubMed Central reports on the latest research, including studies on enteral nutrition and feeding intolerance. Regulatory authorities, such as the US FDA and the EMA, closely monitor and regulate the development and approval process of gastroparesis drugs. Safety, efficacy, pharmacological data, pharmacodynamic effects, and drug interactions are key factors assessed during this process. Failure to meet these criteria may result in a complete response letter (CRL) or rejection. Applicants receiving a CRL must provide additional data to address regulatory concerns. Strict regulations ensure the highest standards of drug sterility and consistency. Discover how AI is revolutionizing market trends- Get your access now! This gastroparesis drugs market report extensively covers market segmentation by 1.1 Prokinetic agents 1.2 Antiemetics 1.3 Botulinum toxin injection 2.1 Idiopathic gastroparesis 2.2 Diabetic gastroparesis 2.3 Post-surgical gastroparesis 3.1 North America 3.2 Europe 3.3 Asia 3.4 Rest of World (ROW) 1.1 Prokinetic agents- Prokinetic drugs play a significant role in managing gastroparesis, a condition characterized by delayed stomach emptying. These medications, such as metoclopramide and domperidone, are popular due to their ability to address the fundamental cause of the condition. While not all prokinetic agents produce a corresponding improvement in stomach emptying, they are effective in alleviating symptoms like nausea, vomiting, and early satiety. Other recent drugs, including ghrelin, motilin, 5-HT4 receptor agonists, and dopamine receptor agonists, are being studied for their potential in gastroparesis treatment. The use of prokinetic agents for symptoms like constipation, caused by decreased motility in the distal GI tract, also increases their demand and drives market growth during the forecast period. Ani Pharmaceuticals offers Reglan, a metoclopramide formulation, for gastroparesis treatment in the US. Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Gastroparesis is a chronic condition characterized by delayed emptying of the stomach, leading to various digestive disruptions such as nausea, vomiting, and abdominal pain. Neurogastrx's tradipitant is a promising new drug for gastroparesis treatment, while metopimazine, deudomperidone, and metoclopramide are common antiemetics used for symptom management. Evoke Pharma and ANI Pharmaceuticals are among the companies involved in gastroparesis drug development. Diabetes, lifestyles including alcohol consumption and tobacco use, and certain medications like Erythromcin can trigger gastroparesis. Innovative drugs under clinical trials aim to address the underlying causes and improve patient outcomes. However, these drugs may carry risks such as liver injury, GI bleeding, acute cholecystitis, and acute pancreatitis. Antiemetics like Reglan have been linked to Tardive Dyskinesia, a serious side effect. Clinical trials are ongoing to evaluate the safety and efficacy of new treatments for gastroparesis. Gastroparesis is a digestive disorder characterized by delayed emptying of the stomach. Neurogastrx's tradipitant is a promising innovative drug under development for gastroparesis treatment. Other prokinetic agents like metopimazine, deudomperidone, and metoclopramide are commonly used for symptom management. Evoke Pharma and ANI Pharmaceuticals are among the companies involved in gastroparesis drug development. Diabetes, lifestyles (alcohol consumption, tobacco use), and certain medications can trigger gastroparesis. Symptoms include nausea, vomiting, abdominal discomfort, and nutrient absorption complications. Diabetic gastroparesis is a common complication in diabetic cases. Hospitals and specialized care centers offer surgical interventions for severe cases, including FDA-cleared procedures. PubMed Central hosts numerous studies on gastroparesis, its causes, and potential treatments. Other conditions like Acute cholecystitis and Acute pancreatitis can also cause gastroparesis. Antiemetics like Erythromycin and Reglan are sometimes used to manage symptoms. Clinical trials are ongoing to explore new treatment options. Autonomic neuropathy is a potential cause of gastroparesis. Prokinetic agents help promote stomach contractions and hinder hindering digestion. Enteral nutrition and feeding intolerance are common complications. 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Drug Class Prokinetic Agents Antiemetics Botulinum Toxin Injection Disease Type Idiopathic Gastroparesis Diabetic Gastroparesis Post-surgical Gastroparesis Geography North America Europe Asia Rest Of World (ROW) 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE TechnavioNow more than two weeks out for his ankle injury, Pittsburgh Steelers outside linebacker Alex Highsmith said he’s “feeling much better” and did not rule out a return to game action at the Cincinnati Bengals on Sunday. During his weekly news conference Tuesday, coach Mike Tomlin said Highsmith was “leaning in on a return.” “We’ll let his participation and the quality of that participation be our guide in terms of whether he gets back in or what degree he gets back in,” Tomlin said. Highsmith suffered a sprain to the “lower” part of his left ankle late during the Nov. 10 win at the Washington Commanders. He has missed two games and not practiced since . The Steelers held a light practice Tuesday. Highsmith did not confirm he participated, but he did say he felt better “running around” Tuesday than he did last week before the Steelers’ mini-bye. “I really have been attacking rehab every single day,” Highsmith said. “I’ve been here doing extra, doing as much as I can just trying to get back Less than a week prior to Highsmith’s injury, the Steelers acquired veteran edge defender Preston Smith. Nick Herbig made a return from a hamstring injury in the interim, and those two have filled Highsmith’s shoes opposite star T.J. Watt on the edge of the Steelers defense. “Progressing every day, that’s my goal,” Highsmith said. “I am aiming to try to get back out there. I’ve got to be confident that I can play on (the ankle).” Trice, Adams on way back? A pair of defensive players who remain on the injured reserve list are respectively “working their way back to us,” Tomlin said. Cornerback Cory Trice is coming up on two weeks since he returned to practice since he suffered a hamstring injury in September. Defensive tackle Montravius Adams has been on IR since Oct. 22 because of a knee injury, and Tomlin hinted that Adams could be cleared to practice this week. “We’ll leave the door open for those guys,” Tomlin said. Once a player on IR returns to practice he has a 21-day window in which his team must activate him if he is to return to game action this season.LLMs may have a killer enterprise app: ‘digital labor’ — at least if Salesforce AgentForce is any indicatorDaniel Jones is signing with Vikings after his release from Giants
A long-standing debt rule helped collapse Germany's government. Now the policy is ripe for reform
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Symbotic Inc. ("Symbotic") common stock SYM . SYM designs and develops an A.I.-powered robotic software platform for use in warehouses. After the market closed on November 18, 2024, SYM announced its fiscal fourth quarter and full year 2024 results. In addition, Symbotic disclosed it would need to restate its financial statements for the first three quarters of fiscal year 2024 with respect to its accounting of goods and services received. Before the market opened on November 27, 2024, Symbotic announced it wouldn't be able to file its Annual Report on Form 10-K for the fiscal year ended September 28, 2024. Symbotic disclosed on November 25, 2024, it had identified errors in its revenue recognition related to cost overruns that are not billable on certain deployments, which additionally impacted system revenue recognized in the first three quarters of fiscal 2024. The total impact of the errors will lower system revenue, system gross profit, income (loss) before income tax, and adjusted EBITDA by $30 million to $40 million for fiscal 2024. Furthermore, Symbotic lowered its fiscal 2025 revenue and adjusted EBITDA guidance by 3.0% and 51.7%, respectively. Pre-market trading for Symbotic on November 27, 2024 indicates Symbotic's stock price will open down over 31% to $25.34 per share. Investors who lost over $25,000 trading in Symbotic common stock and who would like to discuss the investigation should contact Adam Savett at (212) 451-9655, or asavett@wolfpopper.com . Wolf Popper has successfully recovered billions of dollars for defrauded investors. Wolf Popper's reputation and expertise have been repeatedly recognized by courts that have appointed the firm to major positions in securities litigation. For more information about Wolf Popper, please visit the Firm's website at www.wolfpopper.com . Attorney Advertising: Prior Results Do Not Guarantee a Similar Outcome. Wolf Popper LLP Adam Savett 845 Third Avenue New York, NY 10022 Tel.: (212) 451-9655 Email: asavett@wolfpopper.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Atico Mining Co. ( CVE:ATY – Get Free Report ) hit a new 52-week low on Friday . The stock traded as low as C$0.10 and last traded at C$0.10, with a volume of 80150 shares. The stock had previously closed at C$0.12. Atico Mining Price Performance The company has a quick ratio of 1.56, a current ratio of 0.87 and a debt-to-equity ratio of 43.43. The firm has a market cap of C$12.13 million, a PE ratio of -1.43 and a beta of 2.16. The stock has a 50 day moving average price of C$0.14 and a two-hundred day moving average price of C$0.16. Atico Mining Company Profile ( Get Free Report ) Atico Mining Corporation engages in the acquisition, exploration, and development of copper and gold projects in Latin America. The company also explores for silver, lead, and zinc deposits. Its holds interest in the El Roble mine located in Department of Choco, Colombia; and the La Plata project located in Ecuador. Further Reading Receive News & Ratings for Atico Mining Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atico Mining and related companies with MarketBeat.com's FREE daily email newsletter .The United States is a paradox: Media and public opinion polls portray us as a nation divided along partisan lines, but deeper research reveals that Americans share common ground on many core values and political issues. As a political philosopher , I worry about the growing chasm between our shared concerns and the often ugly polarization that divides the electorate. As we gather with family and friends who may have voted for different candidates this Thanksgiving, let’s keep in mind the many things we do agree on. A fuller awareness of our shared principles – particularly on what are so often presented as divisive policy issues – can help us listen to and respect one another over the dinner table conversation, even if it turns to politics. Cultivating political civility and unity in our private lives is a modest yet indispensable act that we all can undertake to defend and nurture the norms and culture of democracy – even if some of our political representatives fail to set the same example in public life. For starters, there is huge agreement among Americans on issues such as taxes, immigration and the economy, a 2023 survey by the American Communities Project found . There is also strong support for fundamental democratic principles , including equal protection under the law, voting rights and our First Amendment freedoms of religion, assembly, speech and the press. Judy Ho Oct. 29, 2024 In survey after survey, a majority of Americans say abortion should be legal in most or all cases. There is also broad support for high-quality health care that is accessible to all . A majority of U.S. citizens acknowledge the reality of human-caused climate change and endorse the development of renewable energy , though they may differ on how to achieve those goals. Too often positions are treated as adversarial when in fact they can be compatible – and voters with nuanced views may actually hold both positions. For example, there is broad support for stronger gun control regulations , as well as support for the right to bear arms. For all the bitterness of the 2024 presidential election, the top concerns were widely shared across party lines. Both Republicans and Democrats ranked the economy as a top political priority. A shared pessimism over the economy clearly helped Donald Trump win the election. On immigration, another key factor in the election, Americans have a positive view of legal immigration , though that sentiment has declined in recent years . Today, most Americans want to see immigration reduced . Part of the tension in the nation’s thinking about immigration stems from a political culture that is more responsive to sensationalism and disinformation than to sober consideration and discussion of the pros and cons of immigration. Much of the discourse was marred by fictional and bigoted tales of immigrants eating pets and false portrayals of most immigrants as criminals . Even shared political perceptions aren’t always based on good evidence or reasons. Despite sharing common ground, Americans perceive the nation as deeply polarized , and constant exposure to disinformation makes it nearly impossible to sort fact from fiction. Indeed, the perception of division can itself fuel distrust where commonality might otherwise be found. This perception of polarization can be exploited by partisans with something to gain. When people are told that experts are divided on an issue, such as climate change, it leads to distrust and polarization . Conversely, emphasizing scientific consensus tends to unify public concern and action. The perception that Americans are more divided than we are poses an enormous threat to democracy. People begin to see even neighbors and family members who vote differently as enemies rather than fellow citizens. Stress about holiday interactions with relatives who voted differently is leading some people to cancel family gatherings rather than spend time together. If people are too busy attacking each other, they will miss opportunities to unite, and they will fail to recognize the real threats to their shared values. Johnny C. Taylor Jr. July 19, 2024 Recognizing the public’s shared values is an important first step in healing political divides. Philosopher Robert B. Talisse has argued that one way to get started might be refocusing attention on nonpolitical community projects that bring together people who don’t normally think of each other as allies. That includes civic or sports clubs and local community events. These are collaborative in a way that supports community identity rather than partisan identity. It is an exercise in rebuilding civic trust and recognizing each other as fellow citizens, and perhaps even friends, without the tension of partisan politics. Once this trust in each other’s civic identity is healed, it can open a door for meaningful political discussion and understanding of each other’s concerns. Including at holiday gatherings. Lawrence Torcello is an associate professor of philosophy at the Rochester Institute of Technology in New York. This commentary was produced in partnership with The Conversation , a nonprofit, independent news organization dedicated to bringing the knowledge of academic experts to the public.
Authorities in Pakistan launch operation to clear Khan supporters from capital
Two-thirds of Wild's top line back together with Eriksson Ek’s return
Short Interest in Banco Bradesco S.A. (NYSE:BBD) Rises By 127.8%UnitedHealthcare CEO Assassin’s Surprise Stop Before Shock Killing of Brian Thompson
Kenny Atkinson , take a bow. The Cavaliers’ new head coach just got his first hardware of the season, named NBA Eastern Conference Coach of the Month for October and November. And honestly? Well-deserved. The guy’s been nothing short of a maestro, leading Cleveland to a ridiculous 18-3 start, tops in the league. Atkinson isn’t one to hog the spotlight, though. Before Thursday’s game against the Wizards, he was quick to deflect credit, calling his team “99% of the reason” for the success. “This is a roster that’s talented, that has great continuity and it’s together,” Atkinson said. “It makes my job a lot easier.” Let’s be real, though — coaching a team to a franchise-best 15-0 start isn’t just about rolling the ball out there. Atkinson’s system has clicked instantly, blending the likes of Donovan Mitchell and Darius Garland with a rising force in Evan Mobley . And, oh yeah, those 15 straight wins? The longest streak to open a season in Cavaliers history and tied for the second-best start ever in the NBA. Not bad company to keep. Cleveland’s dominance isn’t just in the win column. They’re lighting it up offensively, leading the league in points per game (122.4), field goal percentage (.511), and three-point shooting (.402). So far, it’s been modern basketball nirvana. Sprinkle in some defensive grit — they’re seventh in defensive rating — and you’ve got a team that’s looking like a legitimate title contender. Atkinson might be underselling his own impact, but let’s not. He’s pushed this group to levels we haven’t seen in Cleveland since the days of LeBron James . Six games scoring 130 or more points already? That’s a Cavs record. And with 60-something games left, who knows where this ceiling is. One thing’s clear: Cleveland is cooking, and Atkinson’s got all the right ingredients. More Cavaliers | All coverage from Hoops Wire This article first appeared on Hoops Wire and was syndicated with permission.
No. 25 UConn working on climbing back up poll, faces No. 15 BaylorAzincourt Energy Corp. ( CVE:AAZ – Get Free Report ) rose 50% on Friday . The stock traded as high as C$0.02 and last traded at C$0.02. Approximately 253,181 shares changed hands during trading, a decline of 2% from the average daily volume of 259,671 shares. The stock had previously closed at C$0.01. Azincourt Energy Stock Up 50.0 % The firm has a market capitalization of C$4.48 million, a PE ratio of -1.50 and a beta of 2.78. The stock has a 50-day simple moving average of C$0.01 and a 200-day simple moving average of C$0.02. Azincourt Energy Company Profile ( Get Free Report ) Azincourt Energy Corp., an exploration and development company, focuses on the alternative fuels/alternative energy sector in Canada and Peru. It explores for uranium and lithium deposits, as well as other clean energy elements. The company owns interest in the East Preston project covering an area of approximately 25,000 hectares located in Saskatchewan, Canada; and the Big Hill Lithium project covering approximately an area of 7,500 hectares located in southwestern Newfoundland, Canada. See Also Receive News & Ratings for Azincourt Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azincourt Energy and related companies with MarketBeat.com's FREE daily email newsletter .
Cook accepts Hula Bowl invite; Missouri loses its first pair of players to the portal
The Department of Finance (DOF) expects the Philippines to achieve a historic P606.6 billion in non-tax revenues for 2024, exceeding targets by more than 200 percent and surpassing the 2023 total by more than half. “Emerging non-tax revenues for the full year 2024 are expected to reach P606.6 billion—the highest ever recorded,” the DOF said in a Dec. 28 statement. This would surpass the 2024 Budget of Expenditures and Sources of Financing (BESF) target by P407.6 billion and exceed the 2023 figure by P211.8 billion, or 53.6 percent. This, after the government has collected a total of P555.30 billion in non-tax revenues as of end-November, marking a significant (45.6 percent) increase compared to the same period last year. “We need to raise more funds to meet the growing needs of our people,” said Finance Secretary Ralph G. Recto. “On top of tax collections, the non-tax revenue sources help us marshal additional resources to equip the government in delivering more and better services in critical areas like healthcare, education, food security, social protection, and national security,” Recto explained. The DOF boosted non-tax revenues by increasing government-owned and -controlled corporations (GOCC) dividend remittance to 75 percent, privatizing assets, and reallocating unused GOCC funds as directed by Congress. As of Dec. 9, GOCCs remitted P136.29 billion in dividends to the Bureau of the Treasury (BTr), surpassing the P100 billion target and rising 35 percent year-on-year. As per DOF, its privatization efforts yielded P4.44 billion by end-2024, a 129 percent increase year-on-year. Proceeds from these included asset sales, leases, dividends, and more, with a notable P2.9 billion sale of government shares in NLEX Corporation. The government also secured a P30 billion upfront payment from SMC-SAP & Co. Consortium for the Ninoy Aquino International Airport (NAIA) rehabilitation deal, expected to generate P900 billion in revenues over a 15-year term. Excess GOCC funds “On top of these, the DOF has put the excess and unused GOCC funds to efficient use this year, as mandated under Republic Act No. 11975 or the General Appropriation Act (GAA) of 2024,” the DOF stated. Just over a week ago, the DOF remitted P167.23 billion from the Philippine Health Insurance Corporation (PhilHealth) and the Philippine Deposit Insurance Corporation (PDIC) to the BTr. Excess GOCC funds, according to the DOF, were used to finance health benefits, medical equipment, new health facilities, and salary increases for government workers. It also supported counterpart financing for major foreign-assisted projects, including bridges, subways, agriculture, and nutrition initiatives nationwide.